All In Biotech

Drug Trial Radar · NCT07185841

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Jul 1, 2028

Study completion Jan 7, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)

Conditions

  • Wet Age-related Macular Degeneration (AMD)

Interventions

  • HX9428 tabletDrug

    Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I : Dose-Limiting Toxicity (DLT)Time frame: Week 4
  2. Phase II: Mean change of letters from baseline in Best Corrected Visual Acuity(BCVA)Time frame: week 25

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.